Terns Pharmaceuticals, Inc.’s TERN share price has surged by 14.97%, which has investors questioning if this is right time to ...

AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.

Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency.

If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age ...

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...